Skip to main
  1. Stocks
  2. Bicara Therapeutics Inc
  3. Forecast
BCAX

BCAX Stock Forecast & Price Target

BCAX Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 8%

Bulls say

Bicara Therapeutics is attractive because ficerafusp alfa combines EGFR and TGF-β blockade in a single asset, with early data showing deep, durable responses and a clean safety profile that could translate into a differentiated standard-of-care position in HPV-negative R/M HNSCC. Despite Genmab’s strong LiGeR-HN1 readout raising the competitive bar, management says FORTIFI-HN01 is substantially enrolled, the mid-2027 interim remains on track, and the company also has FORTIFI-FLEX plus 3L+ mCRC data expected in January 2027, preserving multiple catalysts. Financially, the company has cash runway into 1H29, while the modeled opportunity is meaningful, including about $1.3 billion in peak sales and $909 million in peak risk-adjusted sales in the US and EU for the lead indication.

Bears say

Bicara Therapeutics is exposed to a challenging commercial and clinical landscape because the model update points to higher-than-expected 3Q R&D and SG&A, signaling escalating operating expense pressure before the company has established meaningful revenue. The competitive position also looks weak, as petosemtamab is described as achieving a first-to-market advantage and capturing prescribing patterns well ahead of ficerafusp alfa, while amivantamab is showing strong activity. Together, these factors suggest Bicara may face a slower and more expensive path to market, with increased dilution risk and a tougher bar for ficerafusp alfa to gain share in solid tumors.

BCAX has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

BCAX Analyst Forecast & Price Prediction

Get the latest BCAX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in BCAX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicara Therapeutics Inc (BCAX) Forecast

Analysts have given BCAX a Buy based on their latest research and market trends.

According to 12 analysts, BCAX has a Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicara Therapeutics Inc (BCAX)


BCAX Analyst Forecast & Price Prediction

Get the latest BCAX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in BCAX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover BCAX stock data and trends